Merck KGaA and Dr. Reddy’s Partner to Develop and Manufacture Biosimilars

Merck KGaA says its Merck Serono division will partner with pharmaceutical company Dr. Reddy’s Laboratories (Hyderabad, India) to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions. Biosimilars are approved versions of innovator biopharmaceutical products after patent expiry. The partnership marks the first step by Merck to enter the biosimilar space...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers